Pilocarpine After Combined Cataract/Trabectome Surgery

• Status: Terminated
• Trial end date: 2021-01-21
• Target enrollment: 0
• Participant gender: All

Summary

Combined cataract + trabectome surgery is a surgery designed to help lower the intraocular pressure (pressure in the eye) and hopefully reduce the need for topical drops, progression of glaucoma, and/or further glaucoma surgeries. The purpose of this study is to assess whether using pilocarpine, a medication which is FDA approved to induce miosis, (in other words cause the pupil to constrict or become smaller) provides additional benefit to the success of Trabectome and cataract surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Levofloxacin; Methylprednisolone; Methylprednisolone Acetate; Methylprednisolone Hemisuccinate; Ofloxacin; Pilocarpine; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate

Criteria

Inclusion Criteria:

• Age Range: 30 to 100 years old

• Patients with ocular hypertension or open angle glaucoma undergoing combined cataract surgery with trabectome in a single surgical center

Exclusion Criteria:

• Patients with previous history of eye surgeries (including laser procedures).